10-K: Cell Source Secures $300,000 in Funding via Promissory Note

Cell Source, Inc. has issued a $300,000 promissory note to Darlene Soave Revocable Trust, part of a series of similar notes, to secure funding.

Summary

• Cell Source, Inc. has issued a promissory note to Darlene Soave Revocable Trust for a principal amount of $300,000, with an original issue discount of $50,000, resulting in a subscription amount of $250,000.
• The note is part of a series of similar notes issued on May 22, 2024, to multiple investors.
• The note matures on November 22, 2024, but may be accelerated by the holder under certain conditions.
• Interest accrues at 10% per annum, calculated on a 360-day year basis, and is payable in cash at maturity.
• The company may prepay the note at any time, and is required to use at least 50% of net proceeds from any debt or equity financing before the maturity date to make mandatory prepayments on a pro rata basis.
• The note is not transferable without the company's prior written consent.
• The company will issue a 10-year warrant to purchase 625,000 shares of common stock at $0.75 per share to the holder.

Sentiment

Score: 6

Explanation: The document is neutral in tone, outlining the terms of a financial agreement. It is neither overly positive nor negative, reflecting a standard business transaction. The inclusion of a warrant is a positive for the investor, but the high interest rate and mandatory prepayment clause are a negative for the company.

Positives

• The company has secured additional funding through the issuance of this promissory note.
• The company has the option to prepay the note at any time, providing flexibility in managing its debt.
• The mandatory prepayment clause ensures that the note will be repaid if the company raises additional capital.

Negatives

• The note is unsecured, meaning the holder has no specific assets to claim in case of default.
• The note is not transferable without the company's consent, limiting the holder's ability to liquidate the investment.
• The company is obligated to use a significant portion of any new financing to repay this note, which may limit its ability to use new capital for other purposes.

Risks

• The company may default on the note if it fails to make payments of principal or interest.
• The company may be unable to raise additional capital to repay the note.
• The company may face legal action if it fails to comply with the terms of the note.
• The company's financial condition may deteriorate, making it difficult to repay the note.

Future Outlook

The document outlines the terms of a debt financing agreement, with no specific forward-looking statements about the company's future performance or prospects.

Industry Context

This type of financing is common for early-stage companies seeking capital, particularly in the biotech sector where research and development costs are high. The use of warrants is also a common incentive for investors in such companies.

Comparison to Industry Standards

• The 10% interest rate is relatively standard for unsecured debt in the biotech sector, reflecting the higher risk associated with these investments.
• The mandatory prepayment clause is a common feature in such notes, protecting investors in case of a successful capital raise by the company.
• The inclusion of warrants is a typical incentive for investors, providing potential upside if the company's stock price increases.
• The terms of this note are similar to other financing agreements in the biotech industry, where companies often rely on debt and equity financing to fund their operations.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised.
• Creditors are provided with a debt instrument that has a mandatory prepayment clause.
• The company's management is obligated to repay the note and manage the company's finances to ensure repayment.

Next Steps

• The company will issue a warrant to the holder.
• The company will make interest payments at maturity.
• The company will make mandatory prepayments if it raises additional capital before the maturity date.

Key Dates

Keywords

promissory note, debt financing, original issue discount, prepayment, warrant, capital raise, unsecured debt, Cell Source, Darlene Soave Revocable Trust